Research indicates new diabetes medication Foundayo available in UK pharmacies improves weight loss — Evidence Review
Published by researchers at Eli Lilly, National Institute for Health and Care Excellence
Researched by
— the AI search engine for science
Table of Contents
A new daily pill, Foundayo (orforglipron), offers UK patients with obesity or type 2 diabetes an oral treatment option for weight loss and blood sugar control. Existing research on GLP-1 receptor agonists broadly supports the benefits of these medications for both weight loss and glycemic improvement. See the original study source for more information.
- Related studies consistently find GLP-1 receptor agonists produce significant weight loss and improved glycemic control in people with type 2 diabetes or obesity, with oral formulations offering similar outcomes to injectables 1 2 4 11 12.
- The introduction of an oral GLP-1 medication like Foundayo aligns with recent evidence that oral GLP-1 drugs are both effective and well-tolerated, although gastrointestinal side effects such as nausea are relatively common 2 11 12.
- Access and uptake of newer anti-diabetic therapies vary across Europe, and concerns about counterfeit drugs highlight the importance of regulated dispensing—a challenge also noted in the broader literature 9.
Study Overview and Key Findings
The availability of Foundayo (orforglipron) in UK pharmacies marks a notable development in obesity and diabetes care. Unlike injectable GLP-1 receptor agonists, Foundayo is an orally administered medication, offering a more accessible treatment for individuals who cannot or prefer not to use injections. Its approval is particularly timely as the demand for effective, safe, and user-friendly weight-loss and diabetes therapies continues to grow, alongside rising concerns about counterfeit drugs in the weight management market. The initial rollout through private prescription, pending NHS assessment, underscores ongoing challenges in equitable access to weight-loss treatments.
| Property | Value |
|---|---|
| Organization | Eli Lilly, National Institute for Health and Care Excellence |
| Population | Patients with diabetes and weight-related conditions |
| Outcome | Weight loss, blood sugar levels improvement |
| Results | Foundayo is now available in UK pharmacies for eligible patients. |
Literature Review: Related Studies
To contextualize the new findings, we searched the Consensus paper database, which contains over 200 million research papers. The following search queries were used to identify relevant studies:
- diabetes medication weight loss effects
- new diabetes treatments UK pharmacies
- oral diabetes drugs patient eligibility criteria
Related Studies: Key Topics and Findings
| Topic | Key Findings |
|---|---|
| How effective are GLP-1 receptor agonists (GLP-1 RAs) for weight loss and glycemic control? | - GLP-1 RAs, including both injectables and oral formulations, are highly effective for weight loss and glycemic control in type 2 diabetes and obesity 1 2 4 11 12. - Oral GLP-1 RAs such as semaglutide demonstrate comparable efficacy to injectables 11 12. |
| What are the safety and tolerability considerations of GLP-1 RAs and other diabetes drugs? | - Gastrointestinal side effects (nausea, vomiting) are common with GLP-1 RAs, but they are generally well-tolerated and safe 2 11 12. - SGLT inhibitors also support weight loss with a different side-effect profile 5. |
| How do newer diabetes medications compare in terms of access, uptake, and cost-effectiveness? | - Uptake of newer anti-diabetic medicines, including GLP-1 RAs, varies significantly across European countries, with cost and prescribing policy as major factors 9 8 10. - Oral medications may improve accessibility, but concerns about counterfeit drugs persist 9. |
| Do clinical pharmacy interventions and route of administration affect outcomes? | - Pharmacist-led interventions improve glycemic control, reduce adverse events and costs, and may enhance access to therapies 7. - Oral GLP-1 drugs expand options for patients unable or unwilling to use injectables, potentially increasing treatment uptake 11 12. |
How effective are GLP-1 receptor agonists (GLP-1 RAs) for weight loss and glycemic control?
A substantial body of evidence shows that GLP-1 RAs, whether injectable or oral, deliver clinically meaningful weight loss and improve glycemic control in adults with type 2 diabetes and/or obesity. The introduction of Foundayo aligns with these findings, as earlier studies on oral semaglutide and other GLP-1 RAs have demonstrated similar efficacy.
- Systematic reviews and meta-analyses confirm GLP-1 RAs lead to significant reductions in weight, BMI, and waist circumference, with consistent benefits across different patient populations 1 2 4.
- Oral GLP-1 RA (semaglutide) has been shown to be as effective as injectable versions in reducing HbA1c and weight 11 12.
- The greatest benefits are often observed in younger, female patients without diabetes, but significant effects are seen in patients with type 2 diabetes as well 4.
- Combining GLP-1 RAs with behavioral interventions further enhances weight loss and metabolic outcomes 3.
What are the safety and tolerability considerations of GLP-1 RAs and other diabetes drugs?
GLP-1 RAs, including oral formulations, are generally well-tolerated, but gastrointestinal side effects are common. The safety profile of GLP-1 RAs is considered acceptable, and oral administration does not appear to increase risk relative to injectables. SGLT inhibitors represent another class with weight loss benefits but have distinct side effects.
- Nausea and vomiting are the most frequently reported adverse effects with GLP-1 RAs; these are usually mild to moderate and transient 2 11 12.
- Oral GLP-1 RAs have a safety profile consistent with their injectable counterparts 11 12.
- SGLT inhibitors also promote weight loss and have a favorable safety profile, but with different potential adverse events, such as risk of urinary tract infections 5.
- No significant increase in hypoglycemic events was observed with GLP-1 RAs in the reviewed trials 3 11 12.
How do newer diabetes medications compare in terms of access, uptake, and cost-effectiveness?
While the clinical efficacy of newer diabetes and weight-loss drugs is clear, access and cost-effectiveness remain significant considerations. Uptake varies across countries due to differences in healthcare policy, cost, and market factors. The introduction of oral medications like Foundayo could improve access, but issues with counterfeit and unregulated products are a concern.
- Market uptake of new antidiabetic drugs varies tenfold across European countries, influenced by policy, cost, and regulatory factors 9.
- Oral medications may be more accessible for patients compared to injectables, but there is an associated risk of counterfeit drugs, particularly in the weight-loss market 9.
- Cost-effectiveness analyses in the UK show that newer GLP-1 RAs can improve health outcomes and reduce long-term costs due to fewer complications 8 10.
- The shift toward pharmacy-led access and private prescriptions, as with Foundayo, may help address the "postcode lottery" of diabetes and obesity care, but only if regulatory oversight is maintained 9.
Do clinical pharmacy interventions and route of administration affect outcomes?
Access to pharmacist-led interventions and the availability of oral medications appear to improve patient outcomes and facilitate broader uptake of effective therapies. Oral GLP-1 RAs are particularly beneficial for patients who cannot or do not wish to use injectables.
- Clinical pharmacy interventions improve glycemic control, reduce adverse events, and lower the cost of diabetes care compared to usual care 7.
- Oral GLP-1 RAs expand options for eligible patients, particularly those who have difficulty with injections, potentially increasing adherence and satisfaction 11 12.
- The route of administration plays a role in patient access and acceptance of therapy, with oral options likely to be preferred by many 11 12.
- Integrating pharmacy-based access to weight-loss and diabetes treatments may help address disparities in care, provided safety and regulation are ensured 7 9.
Future Research Questions
Despite strong evidence for the efficacy and safety of GLP-1 RAs, including oral formulations, several questions remain regarding long-term outcomes, comparative effectiveness, access, and real-world impact. Future research can address these gaps to inform policy, clinical practice, and patient care.
| Research Question | Relevance |
|---|---|
| What are the long-term real-world safety and effectiveness outcomes of oral GLP-1 receptor agonists like Foundayo? | While trial data support efficacy and safety, long-term and real-world data are limited, particularly regarding sustained weight loss, glycemic control, and rare adverse events 2 4 11 12. |
| How does oral GLP-1 therapy compare with injectable formulations in terms of adherence, patient preference, and clinical outcomes? | Understanding differences in adherence and patient-reported outcomes can guide optimal therapy selection and improve long-term success 11 12. |
| What strategies can effectively address the risk of counterfeit weight-loss medications in the market? | The proliferation of unlicensed and counterfeit drugs poses safety risks and undermines public health efforts, requiring research into regulatory and technological solutions 9. |
| How cost-effective are oral GLP-1 receptor agonists for weight loss and diabetes management within public health systems? | Analyses of cost-effectiveness in real-world settings will inform policy and access decisions, especially in publicly funded health systems like the NHS 8 10. |
| What are the barriers and facilitators to equitable access to new oral diabetes medications in different healthcare settings? | Addressing disparities in access will ensure that innovations like Foundayo benefit the widest possible range of patients, reducing the "postcode lottery" in care 9. |